Oligonucleotide Therapy Global Market Report 2024: Market Overview

The oligonucleotide therapy market size has grown rapidly in recent years. It will grow from $4.9 billion in 2023 to $5.61 billion in 2024 at a compound annual growth rate (CAGR) of 14.4%. The growth in the historic period can be attributed to growth in investment in research and development, market entry of early therapies, rise of gene editing techniques, early therapeutic discoveries, rnai and antisense oligonucleotide introduction.

The oligonucleotide therapy market size is expected to see rapid growth in the next few years. It will grow to $8.75 billion in 2028 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to research and development investments, global market penetration, therapeutic area expansion, disease modification strategies, regulatory adaptations. Major trends in the forecast period include customized therapies, advancements in delivery systems, rna interference (rnai) advancements, antisense oligonucleotide innovation, gene editing techniques integration.

Market Overview -
Oligonucleotide therapy refers to a collective term for cutting-edge molecular-targeting agents that use chemically produced oligonucleotides with single-stranded DNA (DNA) or RNA (RNA) backbones that have the potential for selectivity. Oligonucleotides are made to base-pair with a strand of DNA or RNA for the majority of applications. PCR primers are oligonucleotides' most popular application (polymerase chain reaction)

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=3398&type=smp

Increasing Cancer Epidemic Driving Growth In The Oligonucleotide Therapy Market
The rise in the number of cancer cases across the globe is likely to contribute to the growth of the oligonucleotide therapy market during the forecast period. For instance, in January 2022, according to the American Cancer Society, there will likely be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, or roughly 1,670 fatalities every day. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43 percent of all new cancer cases. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all new cancer cases. Therefore, the rise in cancer incidence rates globally is anticipated to boost demand for the oligonucleotide therapy market over the forthcoming years.

Competitive Landscape -
Major companies operating in the oligonucleotide therapy market report are Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Gelead Sciences Inc., BioNTech SE, Moderna Inc., Biogen Inc., Bausch + Lomb Company, Jazz Pharmaceuticals plc, QIAGEN Company, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Dynavax Technologies Corp., Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals lnc., SomaGenics Inc., Wave Life Sciences Ltd., Exicure Inc., Hepion Phrmaceuticals lnc., Avidity Biosciences lnc., Miragen Therapeuutics Inc., ProQR Therapeutics NV, Regulus Therapeutics Inc., PCI Biotech Holdings ASA, Kastle Therapeutics LLC, Santaris Pharma A/S, InteRNA Technologies B.V., Dynacure S.A., Arcturus Therapeutics Holdings Inc., Intellia Therapeutics Inc., Regeneron Pharmaceuticals Inc., Editas Medicine Inc., Evox Therapeutics Ltd., ONK Therapeutics Ltd., PepGen Ltd.

Innovative Oligonucleotide Therapy Advancements Pioneering Patient-Centric Solutions
The developers and providers of the oligonucleotide therapy market are investing in research and development to remodel the design of therapy to reduce its side effects on patients. The new and innovative oligonucleotides allow for precision medicine approaches and can be designed to selectively target any gene with minimal side effects. It also helps in targeting patient-specific sequences that are causative of rare diseases. In April 2023, the FDA approved Qalsody, an antisense oligonucleotide (ASO), for the treatment of patients with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene. Qalsody targets SOD1 mRNA to reduce the synthesis of SOD1 protein

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/oligonucleotides-therapy-global-market-report

Key Segments -

The oligonucleotide therapy market covered in this report is segmented -

1) By Type: Antisense Oligonucleotide, Aptamer, Other Types
2) By Application: Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, Kidney Diseases, Other End-User
3) By End User: Hospitals, Research Institutes

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.